Changes related to kidney staining in UUO mouse model. by Wencheng Jin (13136262)

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Changes associated with kidney fibrosis in TGF- by Wencheng Jin (13136262)

The screening process of MN705. by Wencheng Jin (13136262)

Validation of MN705 treatment effects in human proximal tubular epithelial cells during TGF- by Wencheng Jin (13136262)

Age-specific burden of IHD attributable to HSBP for males and females in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Global burden of IHD attributable to HSBP from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific estimated annual percentage changes in DALYs and death rates for 21 regions from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. by Zhenhua Zhuang (11192745)

Subjects:

Effect of MN705 treatment on TGF- by Wencheng Jin (13136262)

Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. by Rachael M. Giersch (22331947)

Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…</p><p>Results</p><p>During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of −0.36% in HbA1c levels between the groups (95% CI: −0.54 – −0.19, P < 0.01). …”

Supplementary Tables 1–8. by Juliane F. Tampé (19976538)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: